Vancomycin Hydrochloride Capsules, USP Product Monograph

SUMMARY PRODUCT INFORMATION

INDICATIONS AND CLINICAL USE

Vancomycin Hydrochloride Capsules, USP are indicated for treatment of infections caused by susceptible strains of the designated microorganisms in the following diseases and specific conditions:

staphylococcal enterocolitis, and

antibiotic-associated pseudomembranous colitis produced by Clostridium difficile.

Parenteral administration of vancomycin hydrochloride is not effective for the indicated conditions; therefore vancomycin hydrochloride must be given orally.

Vancomycin Hydrochloride Capsules, USP is not effective by the oral route for the treatment of other types of infection.

Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety and a brief discussion can be found in the Warnings and Precautions section.

Pediatrics: Evidence from clinical studies and experience suggests that use in premature neonates and young infants is associated with differences in safety and a brief discussion can be found in the Warnings and Precautions section.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride and other antibacterial drugs, vancomycin hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Because some strains

are resistant to vancomycin, when applicable, appropriate specimens should be obtained before antibacterial treatment, to determine the causative organism(s) and susceptibility to vancomycin.

CONTRAINDICATIONS

Vancomycin Hydrochloride Capsules, USP is contraindicated for patients who are hypersensitive to vancomycin hydrochloride or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section.

WARNINGS AND PRECAUTIONS

General

Vancomycin hydrochloride is poorly absorbed orally. Toxic serum levels are therefore not expected from oral dosage. Clinically significant serum concentrations have been reported in some patients who have taken multiple oral doses of vancomycin for active C. difficile-induced pseudomembranous colitis; therefore, monitoring of serum concentrations may be appropriate in these patients.

When given intravenously, toxic serum levels can occur. During parenteral therapy, the risk of toxicity appears appreciably increased by high blood concentrations or prolonged treatment.

Ear/Nose/Throat

Ototoxicity has occurred when serum levels exceeded 80 mcg/mL. Deafness may be preceded by tinnitus. Deafness may be transient or permanent. The elderly are more susceptible to auditory damage. Deafness may be progressive despite cessation of treatment.

Vancomycin hydrochloride should be avoided (if possible) in patients with previous hearing loss. If it is used in such patients, the dose of vancomycin hydrochloride should be regulated by periodic determination of drug levels in the blood. Patients with renal insufficiency and individuals over the age of 60 should be given serial tests of auditory function and of vancomycin blood levels.

Gastrointestinal

Some patients with inflammatory disorders of the intestinal mucosa may have significant systemic absorption of oral vancomycin and, therefore, may be at risk for the development of adverse reactions associated with the parenteral administration of vancomycin. The risk is greater if renal impairment is present.

Hematologic

Neutropenia can occur starting one week or more after onset of therapy with vancomycin hydrochloride or after a total dose of more than 25 g. Neutropenia appears to be promptly reversible when treatment is discontinued.

Renal

Because of its ototoxicity and nephrotoxicity, vancomycin hydrochloride should be used with care in patients with renal insufficiency. Vancomycin is excreted fairly rapidly by the kidney and blood levels increase markedly with decreased renal clearance. There is an increased risk of renal failure in patients receiving large doses of vancomycin hydrochloride.

In patients with underlying renal dysfunction or those receiving concomitant therapy with an aminoglycoside there is a risk of developing interstitial nephritis. When these patients are being treated with vancomycin hydrochloride, serial monitoring of renal function should be performed.

Susceptibility/Resistance

Development of Drug Resistant Bacteria

The prolonged use of vancomycin hydrochloride may result in overgrowth of non-susceptible organisms. If new infections due to bacteria or fungi appear during therapy with this product, appropriate measures should be taken, including withdrawal of vancomycin hydrochloride .

In vitro resistance to vancomycin has been reported among some enterococcal and staphylococcal isolates.

Vancomycin is not effective in vitro against gram-negative bacilli, mycobacteria, or fungi.

Prescribing vancomycin hydrochloride in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria.

Special Populations

Pregnant Women:

Vancomycin hydrochloride should be given to pregnant women only if clearly needed. In a controlled study, Vancomycin hydrochloride was administered to 10 pregnant women for serious staphylococcal infections complicating intravenous drug abuse to evaluate potential ototoxic and nephrotoxic effects on the infant. Vancomycin hydrochloride levels of 13.2 and 16.6 mcg/mL were measured in cord blood in two patients. No sensorineural hearing loss or nephrotoxicity attributable to vancomycin hydrochloride was noted. One infant whose mother received vancomycin hydrochloride in the third trimester experienced conductive hearing loss that was not attributed to the administration of vancomycin hydrochloride. Because the number of patients treated in this study was limited and vancomycin hydrochloride was administered only in the second and third trimesters, it is not known whether vancomycin hydrochloride causes fetal harm.

Nursing Women:

Vancomycin hydrochloride is excreted in human milk. Caution should be exercised if vancomycin hydrochloride is administered to a nursing woman. Because of the potential for adverse events, a decision should be made whether to discontinue nursing or discontinue administration of the drug, taking into account the importance of the drug to the mother.

Pediatrics (premature neonates and young infants):

It may be appropriate to confirm desired vancomycin serum concentrations. Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing in children.

Geriatrics:

The natural decrease of glomerular filtration with increasing age may lead to elevated vancomycin serum concentrations if dosage is not adjusted. Vancomycin dosage schedules should be adjusted in elderly patients. It should be noted that the total systemic and renal clearances of vancomycin are reduced in the elderly. The elderly are more susceptible to auditory damage.

Monitoring and Laboratory Tests:

All patients receiving the drug should have periodic hematologic studies, urinalyses, and liver and renal function tests.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

Nephrotoxicity:

Rarely, renal failure, principally manifested by increased serum creatinine or blood urea nitrogen (BUN) concentrations, especially in patients given large doses of vancomycin hydrochloride has been reported. Rare cases of interstitial nephritis have been reported. Most of these have occurred in patients who were given aminoglycosides concomitantly or who had pre-existing kidney dysfunction. When vancomycin hydrochloride was discontinued, azotemia resolved in most patients.

Ototoxicity:

A few dozen cases of hearing loss associated with vancomycin hydrochloride have been reported. Most of these patients had kidney dysfunction, pre-existing hearing loss, or concomitant treatment with an ototoxic drug. Vertigo, dizziness, and tinnitus have been reported rarely.

Hematopoietic:

Reversible neutropenia, usually starting one week or more after onset of therapy with vancomycin hydrochloride or after a total dose of more than 25 g, has been reported in several dozen patients. Neutropenia appears to be promptly reversible when vancomycin hydrochloride is discontinued. Thrombocytopenia has rarely been reported. Although a causal relationship has not been established, reversible agranulocytosis (granulocyte count less than 500/mm³) has been reported rarely. Eosinophilia has been associated with the administration of vancomycin hydrochloride.

Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome (DRESS)

Toxic Epidermal Necrolysis (TEN)

Miscellaneous:

Anaphylaxis, drug fever, nausea, chills, hypotension, wheezing, dyspnea, urticaria, pruritus, flushing of the upper body (“red neck”), pain and muscle spasm of the chest and back, rashes, including exfoliative dermatitis, Stevens-Johnson syndrome, linear IgA bullous dermatosis and rare cases of vasculitis have been associated with the administration of vancomycin hydrochloride.

DRUG INTERACTIONS

Overview

Drug-Drug Interactions

Concurrent and sequential use of other neurotoxic and/or nephrotoxic agents, particularly ethacrynic acid, neuromuscular blocking agents, aminoglycoside antibiotics, polymixin B, colistin, viomycin, and cisplatin, requires careful monitoring.

Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing in children.

Drug-Food Interactions

Interactions studies between vancomycin hydrochloride and food have not been conducted.

Drug-Herb Interactions

Interactions studies between vancomycin hydrochloride and herbs have not been conducted.

Drug-Laboratory Test Interactions

Interactions studies between vancomycin hydrochloride and laboratory tests have not been conducted.

DOSAGE AND ADMINISTRATION

Dosing Considerations

If parenteral and oral vancomycin are administered concomitantly an additive effect can occur. This should be taken into consideration when calculating the total dose. In this situation serum levels of the antibiotic should be monitored.

Vancomycin Hydrochloride Capsules, USP capsules are formulated in a matrix gel that prevents administration by a nasogastric tube; if this route of administration is being considered; the intravenous dosage form should be used.

Recommended Dose and Dosage Adjustment

Adults:

The usual daily dosage for antibiotic-associated pseudomembranous colitis produced by C. difficile

and staphylococcal enterocolitis is 125 to 500 mg administered orally every 6 to 8 hours for 7 to 10 days.

Pediatrics:

The usual daily dosage is approximately 40 mg/kg in 3 or 4 divided doses for 7 to 10 days administered orally. The total daily dosage should not exceed 2 g.

Missed Dose

If a dose of this medication has been missed, it should be taken as soon as possible. However, if it is almost time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double doses.

OVERDOSAGE

Activated charcoal may be administered to aid in the removal of unabsorbed drug. General supportive measures are recommended.

Other than general supportive treatment, no specific antidote is known. Dialysis does not remove significant amounts of vancomycin. Hemofiltration and hemoperfusion with polysulfone resin have been reported to result in increased vancomycin clearance.

In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in the patient.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

In vitro studies indicate that the bactericidal action of vancomycin hydrochloride against many gram-positive bacteria results from the inhibition of cell-wall synthesis. There is also evidence that vancomycin alters the permeability of the cell membrane and selectively inhibits RNA synthesis.

STORAGE AND STABILITY

Temperature:

• Store vancomycin capsules at room temperature (15° to 25°C).

Moisture:

• Protect from moisture.

Others:

• Keep out of sight and reach of children.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Vancomycin Hydrochloride Capsules, USP contain vancomycin hydrochloride, (expressed in terms of free base) and polyethylene glycol 6000. The capsules also contain FD&C Blue No.2, gelatin, iron oxide, and titanium dioxide.

Vancomycin Hydrochloride Capsules, USP equivalent to 125 mg (0.08 mmol) vancomycin and 250 mg (0.17 mmol) vancomycin are available in (unit-dose) packages of 20 capsules.

Vancomycin Hydrochloride Capsules, USP 125 mg: A size 2, grey/light grey hard gelatin capsule with a white to slightly red or slightly brown solid mass.

Vancomycin Hydrochloride Capsules, USP 250 mg: A size 0, green/turquoise hard gelatin capsule with a white to slightly red or slightly brown solid mass.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: Vancomycin hydrochloride

Chemical Name:

(Sa)-(3S,6R,7R,22R,23S,26S,36R,38aR)-44-[[2-0-(3-Amino-2,3, 6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl] oxy]-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,24, 25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6- [(2R)-4-methyl-2-(methylamino)valeramido]-2,5,24,38,39-pentaoxo- 22H-8,11:18,21-dietheno-23,36-(iminomethano)-13,16:31,35- dimetheno-1H,16H-[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16] -benzoxadiazacyclo-tetracosine-26, carboxylic acid, monohydrochloride

Molecular formula: C₆₆H₇₅Cl₂N₉O₂₄ ·HCl

Molecular mass: 1485.68 g/mol

Structural formula:

Physicochemical properties: Vancomycin hydrochloride is a chromatographically purified tricyclic glycopeptide antibiotic derived from Amycolatopsis orientalis (formerly Nocardia orientalis). It is an off-white free flowing powder, having essentially no odour. It is soluble in water and insoluble in organic solvents.

DETAILED PHARMACOLOGY

Human Pharmacology

Adults:

Renal Insufficiency:

Infusions of 1 g vancomycin in 250 mL D5W were given over 30 minutes to 29 anephric patients. After 18 days with intermittent dialysis at three-day intervals, the serum concentration was still 3.5 mcg/mL. The elimination half-life was about 7.5 days.

Oral Administration:

Vancomycin hydrochloride is poorly absorbed after oral administration, only trace amounts being found in blood or urine. Following 125 mg orally 4 times daily, the mean concentration of vancomycin in stools was approximately 350 mcg/g. Following up to ten daily oral doses of 2 g, a mean level of 3100 mcg/g with a range of 905 - 8760 mcg/g was detected in feces of patients with pseudomembranous colitis.

Tissue Penetration and Distribution:

Central Nervous System:

Vancomycin does not readily diffuse across normal meninges into the spinal fluid; but, when the meninges are inflamed, penetration into the spinal fluid occurs.

Other Tissues and Fluids:

Vancomycin concentration in human pericardial, pleural, bile, ascetic and synovial fluids reaches approximately one third of the equivalent serum level after single intravenous doses. A level of 7.6 mcg/mL was achieved in the brain cyst of one infant following intravenous infusion of 40 mg/kg daily for 4 days.

MICROBIOLOGY

Cross-resistance has not been demonstrated between vancomycin hydrochloride and other classes of antibiotics. Laboratory-induced resistance has been reported to occur in a slow stepwise fashion. Its activity is not significantly altered by changes in pH or by the presence of serum.

Vancomycin is active against most strains of the following organisms in vitro and in clinical infections as described in the section INDICATIONS AND CLINICAL USE:

Staphylococcus aureus (including heterogeneous methicillin-resistant strains) Clostridium difficile

Vancomycin is active against most strains of the following organisms in vitro. However, the safety and effectiveness of vancomycin in treating clinical infections due to these organisms have not been established in adequate and well-controlled trials.

Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains) Streptococcus pneumoniae (including multiple-resistant strains) Streptococcus pyogenes (group A beta-hemolytic)

Streptococcus agalactiae (group B beta-hemolytic)

Streptococcus bovis

Alpha-hemolytic streptococci (viridans groups)

Enterococci (e.g. E. faecalis)

Bacillus sp.

Listeria monocytogenes

Lactobacillus sp.

Neisseria sp.

Diphtheroids

Actinomyces sp.

Note: Many strains of streptococci, staphylococci, C. difficile, and other gram-positive bacteria are susceptible in vitro to concentrations of 0.5 to 5 mcg/mL. Staphylococci are generally susceptible to less than 5 mcg/mL of vancomycin hydrochloride, but a small proportion of S. aureus strains require 10 to 20 mcg/mL for inhibition.

In vitro resistance to vancomycin has been reported among some enterococcal and staphylococcal isolates.

Vancomycin is not effective in vitro against gram-negative bacilli, mycobacteria, or fungi.

Table 1: In Vitro Activity of Vancomycin

Organism No. of Strains MIC* (mcg/mL) Range Median

Staphylococcus aureus 55 1.0 – 2.0 1.0

101 0.78 – 12.5 3.1 35 0.25 – 1.0 1.0 Staphylococcus aureus

(methicillin-resistant)

22 0.5 – 4.0 0.5 38 0.3 – 12.0 1.5 12 0.2 – 3.12 0.4 Streptococcus epidermidis 177 1.56 – 6.25 3.1

35 0.4 – 3.1 1.6 27 0.2 – 6.25 3.12 Streptococcus pneumoniae 70 0.125 – 0.5 0.25 Streptococcus pyogenes 12 0.8 – 3.1 1.6 Streptococcus viridans 82 0.39 – 1.56 0.78 Streptococcus group D

Enterococci

382 0.8 - > 100.0 3.1

Clostridium perfringens 43 0.4 – 1.6 0.8 Clostridium ramosum 49 3.1 – 12.5 6.2 Clostridium difficile 14 < 1.0 < 1.0 78 1.0 – 4.0

*Minimum Inhibitory Concentration (MIC)

Methods of Susceptibility Testing:

When the standardized method of disc susceptibility testing is used, a 30 mcg disc of vancomycin should produce a zone of more than 11 mm when in contact with “susceptible” organisms. A zone size of 10 – 11 mm indicates intermediate susceptibility, while a zone size of 9 mm or less indicates resistance.

With the WHO-ICS agar dilution and broth dilution methods, a MIC of <5 mcg/mL indicates susceptibility to vancomycin.

Assay Methods:

Vancomycin serum and tissue levels may be determined by Bennett’s agar-well diffusion method. This test can quantitatively measure vancomycin concentrations from 0.5 to 0.8 mcg/mL. Two disc-diffusion assay methods are available for vancomycin. Both use Bacillus subtilis as the test organism. The first method, which uses antibiotic medium No. 5, is capable of measuring

vancomycin levels from approximately 5 to 40 mcg/mL. The second uses minimal salt agar and is capable of detecting vancomycin concentrations from about 0.8 to 25 mcg/mL.

A modification of this assay permits reliable bioassay for vancomycin (in concentrations of 0.78 to 50.0 mcg/mL) in the presence of rifampin or aminoglycosides. Two commercially prepared assay methods are now available and include a radioimmunoassay and an automated fluorescence polarization immunoassay.

TOXICOLOGY

Acute Toxicity

Vancomycin was administered to mice, rats and dogs by various routes.

Table 2: LD₅₀ ± SE (mg/kg) following vancomycin administration

Rats died quickly from CNS-mediated effects, while dogs died, generally from kidney failure, several days after the intravenous administration.

Vancomycin, when administered intravenously in a 5 percent solution to dogs at a rate of 0.6 mL/minute, caused a slight dose-related drop in blood pressure. When the same dogs were given the same doses at a rate of 15 mL/minute, blood pressure dropped dramatically, as much as 40 percent. Whether the response is due to a direct effect on histamine receptors or to release of histamine, possibly from mast cells, is not known.

Subchronic Toxicity

Dogs were given daily intravenous doses of vancomycin at 12.5 mg and 50 mg/kg for 21 - 311 days. Renal damage was seen in 4/22 dogs receiving 50 mg/kg/day.

Monkeys tolerated intravenous doses of 25 and 50 mg/kg/day for 16 - 187 days, with irritation at the injection site as the only toxic effect.

Cats received intravenous doses of 25 and 50 mg/kg/day for three months with no systemic toxicity.

Anaphylaxis could not be induced in 9 guinea pigs that received 100 mg vancomycin subcutaneously when challenged by a 25 mg intravenous dose, 25 days later.

Intraperitoneal doses of 150 mg vancomycin or 60 mg tobramycin given subcutaneously to rats, resulted in no nephrotoxicity; however, when administered together, significant renal toxicity occurred.

Vancomycin 1 000 mg/kg administered subcutaneously concurrently with ethacrynic acid 40 mg/kg intravenously, did not produce ototoxicity in a guinea pig model.

Neuromuscular blocking has not been demonstrated in vancomycin-treated rabbits.

REFERENCES

1. 1.

   Bartlett JG. Antibiotic-associated pseudomembranous colitis. Hospital Practice (Off

   Ed). 1981 Dec; 16 (12):85-8, 93-5. PubMed PMID: 6796495.

2. 2.

   Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect

   Dis. 1984 Mar-Apr; 6 Suppl 1:S235-S241. PubMed PMID: 6718937.

3. 3. Burdon DW. Treatment of pseudomembranous colitis and antibiotic-associated diarrhoea. J Antimicrob Chemother. 1984 Dec: 14Suppl. D:103-9. Review. PubMed PMID: 6394575.
4. 4. Cooper GL, Given DB. Vancomycin – a comprehensive review of 30 years of clinical experience. Park Row Publishers Inc. Jan 1986.
5. 5.

   Cunha BA, Ristuccia AM. Clinical usefulness of vancomycin. Clin. Pharm. 1983 Sep-

   Oct; 2 (5): 417-424. Review. PubMed PMID: 6354567.

6. 6. Dudley MD, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med. 1986 Jun; 146 (6):1101-4. PubMed PMID: 3521518.
7. 7.

   Fekety R. Recent advances in management of bacterial diarrhea. Rev Infect Dis. 1983

   Mar-Apr; 5(2): 246-57. PubMed PMID: 6405474.

8. 8. Fekety R, Silva J, Buggy B, Deery HG. Treatment of antibiotic-associated colitis with vancomycin. J Antimicrob Chemother. 1984 Dec; 14 Suppl D:97-102. PubMed PMID: 6520070.
9. 9. Finegold SM, Gaylor DW. Enterocolitis due to phage type 54 staphylococci resistant to kanamycin, neomycin, paromomycin and chloramphenicol. N Engl J Med. 1960 Dec 1; 263:1110-6. PubMed PMID: 13699584.
10. 10. Geraci JE, Heilman FR, Nichols DR, Wellman WE. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report. Proc Staff Meet Mayo Clinic. 1958 Apr 2; 33 (7):172-81. PubMed PMID: 13542649.
11. 11. Geraci JE, Heilman FR, Nichols DR, Ross GT, Wellmann WE. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Proc Staff Meet Mayo Clinic. 1956 Oct 17; 31 (21):564-82. PubMed PMID: 13370625.
12. 12.

    Geraci JE, Hermans PE. Vancomycin. Mayo Clinic Proc. 1983 Feb; 58 (2):88-91.

    PubMed PMID: 6823162.

13. 13.

    Griffith RS. Vancomycin use – an historical review. J Antimicrob Chemother. 1984

    Dec;14 Suppl D:1-5. PubMed PMID: 6394574.

14. 14. Griffith RS, Peck FB Jr. Vancomycin, a new antibiotic. III. Preliminary clinical and laboratory studies. Antibiot Annu. 1955-1956; 3: 619-22. PubMed PMID: 13355338.
15. 15. Kaplan EL. Vancomycin in infants and children: A review of pharmacology and indications for therapy and prophylaxis. J Antimicrob Chemother. 1984 Dec; 14 Suppl D: 59-66. Review. PubMed PMID: 6394578.
16. 16. Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: Microbiologic and clinical observations as guides to therapy. Ann Intern Med. 1983 Apr; 98 (4):447-455. PubMed PMID: 6838067.
17. 17.

    Keighley MR. Pseudomembranous colitis. Schweiz Rundsch Med Prax. 1982 Jan 19;

    71 (3): 98-106. PubMed PMID: 7038661.

18. 18.

    Khan MY, Hall WH. Staphylococcal enterocolitis – treatment with oral vancomycin.

    Ann Intern Med. 1966 Jul; 65(1): 1-8. PubMed PMID: 5936663.

19. 19.

    Kirby WMM. Vancomycin therapy of severe staphylococcal infections. J Antimicrob

    Chemother. 1984 Dec; 14 (Supp. D):73-8. PubMed PMID: 6394579.

20. 20. Marrie TJ, Furlong M, Faulkner RS, Sidorov J, Haldane EV, Kerr EA. Clostridium difficile: Epidemiology and clinical features. Can J Surg. 1982 Jul; 25(4):438-442. PubMed PMID: 7093841.
21. 21. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984 Apr; 25(4):433-7. PubMed PMID: 6732213; PubMed Central PMCID: PMC185546.
22. 22. McCormick MH, McGuire JM, Pittenger GE, Pittenger RC, Stark WM. Vancomycin, a new antibiotic. I. Chemical and biologic properties. Antibiotics Annu. 1955-1956; 3: 606-11. PubMed PMID: 1355336.
23. 23. McGuire JM, Wolfe RN, Ziegler DW. Vancomycin a new antibiotic. II. In vitro antibacterial studies. Antibiot Annu. 1955-1956;3: 612-8 PubMed PMID: 13355337.
24. 24.

    McHenry MC, Gavan TL. Vancomycin. Pediat Clin North Am. 1983 Feb; 30 (1): 31-

    37.PubMed PMID: 6338468.

25. 25.

    Moellering RC Jr. Pharmaokinetics of vancomycin. J Antimicrob Chemother. 1984 Dec;

    14 Suppl D: 43-52. Review. PubMed PMID: 6394577.

26. 26.

    Pfaller MA, Krogstad JD, Granich GG, Murray PR. Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay. J Clin

    Microbiol. 1984 Sep; 20 (3):311-6. PubMed PMID: 6386852; PubMed Central PMCID: PMC271319

27. 27. Shuttleworth R, Taylor M, Jones DM. Antimicrobial susceptibilities of Clostridium difficile. J. Clin Pathol. 1980 Oct; 33 (10):1002-5. PubMed PMID: 7430354; PubMed Central PMCID: PMC1146303.
28. 28.

    Thomas DF, Fernie DS, Malone M, Bayston R, Spitz L. Association between

    Clostridium difficile and enterocolitis in Hirschsprung’s Disease. Lancet. 1982 Jan 9; 1 (8263):78-9. PubMed PMID: 6119496.

29. 29. Wallace JF, Smith RH, Petersdorf RG. Oral administration of vancomycin in the treatment of staphylococcal enterocolitis. N Engl J Med. 1965 May 13; 272:1014-5. PubMed PMID: 14279249.
30. 30.

    Watanakunakorn C. Mode of action and in vitro activity of vancomycin. J Antimicrob

    Chemother. 1984 Dec; 14 Suppl D: 7-18. Review. PubMed PMID: 6440886.

31. 31.

    Welch DF, Marks MI. Is Clostridium difficile pathogenic in infants? Pediatr. 1982 Mar;

    100(3): 393-5. PubMed PMID: 7062169.

32. 32.

    Wise RI, et al. The vancomycin symposium: summary and comments. Rev Infect Dis.

    1981 Nov-Dec; 3:S293-300.

33. 33. Woodley DW, Hall WH. The treatment of severe staphylococcal infections with vancomycin. Ann Intern Med. 1961 Aug; 55:235-49. PubMed PMID: 13786545.
34. 34.

    VANCOCIN^® (Vancomycin Hydrochloride Capsules), Innovator Product

    Monograph, Merus Labs Inc., Control No.203124, October 27, 2017.